Skip Navigation



Human Molecular Genetics Advance Access published online on December 18, 2007
Human Molecular Genetics, doi:10.1093/hmg/ddm366
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow All Versions of this Article:
17/7/936    most recent
ddm366v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Yan, J.
Right arrow Articles by Yang, F.-C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, J.
Right arrow Articles by Yang, F.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1

Jincheng Yan§,1,2,3, Shi Chen§,1,2, Yingze Zhang3, Xiaohong Li1,2, Yan Li1,2, Xiaohua Wu1,2, Jin Yuan1,2, Alexander G. Robling4, Reuben Kapur1,2,5, Rebecca J. Chan1,2 and Feng-Chun Yang1,2,*

1 Department of Pediatrics, Indiana University School of Medicine 2 Herman B Wells Center for Pediatric Research, Indiana University School of Medicine 3 Hebei Medical University, Shijiazhuang, China 4 Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202

* Corresponding Author: Feng-Chun Yang, M.D.-Ph.D. Indiana University School of Medicine, Cancer Research Institute, 1044 W. Walnut St., R4/427, Indianapolis, IN 46202, Phone: (317) 274-4178, Fax: (317) 274-8679, E-mail: fyang{at}iupui.edu

Received October 30, 2007; Revised December 5, 2007; Accepted December 5, 2007

Neurofibromatosis type I (NF1) is a congenital disorder resulting from loss-of-function of the tumor suppressor gene, NF1, a GTPase-activating protein (GAP) for p21ras. Fifty percent of NF1 patients have osseous manifestations including a high incidence of osteoporosis. Osteoclasts are specialized macrophage/monocyte lineage-derived cells that resorb bone and NF1 haploinsufficient osteoclasts have abnormal Ras-dependent bone resorption. Ras-regulated functions are in part mediated via the activation of small Rho family of GTPases including the Rac-GTPases. In the present study, we demonstrate that the Rho-GTPase Rac1 is a crucial Ras-mediated effector in Nf1 haploinsufficient (+/-) osteoclasts. Nf1+/- mice were intercrossed with conditional Rac1flox/floxMxcre+ (Rac1-/-) mice to generate Nf1+/-;Rac1-/- mice. Genetic disruption of Rac1 restored the pathological increase in osteoclast progenitor cells in Nf1+/- mice and was sufficient to correct the increased Nf1+/- osteoclast motility and osteoclast belt formation, an f-actin structure observed in mature osteoclasts critical for bone resorption and lytic activity. Finally, we demonstrate that Nf1+/-;Rac1-/- osteoclasts have normalized Erk activation compared to Nf1+/- osteoclasts, a biochemical function critical for osteoclast formation, actin organization, and motility. Collectively, these data demonstrate that Rac1 critically contributes to increased osteoclast function induced by haploinsufficiency of Nf1 and implicate Rac1 as a rational therapeutic target for osteoporosis.

§ These authors contributed equally to this work


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.